Skip to content
Clinical Trials – home

Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.

Research site

Poland Ul. Piotra Niedurnego 50 D, 41-709 Ruda Slaska, Poland

  • 5 trials recruiting
  • Obesity · Overweight · Type 2 diabetes mellitus
  • Adult patients

About Specializations

Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j. in Ruda Slaska, Poland specialises in clinical trials of conditions such as Obesity, Overweight, Type 2 diabetes mellitus, Chronic kidney disease, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The site conducts research aimed at improving outcomes for patients with cardiovascular disease, including those at high risk of heart attacks or strokes, by testing innovative therapies that may lower event rates.

  • Evaluation of novel lipid‑lowering agents
  • Assessment of cardiovascular event reduction
  • Study of outcomes in atherosclerotic disease
  • Investigation of kidney‑related cardiovascular risk

Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki contributes to advancing heart health through these trials.

Nervous System Diseases

Trials at the clinic focus on alleviating painful symptoms of diabetic peripheral neuropathy, exploring new analgesic compounds that could enhance quality of life for affected adults.

  • Pain management strategies for diabetic neuropathy
  • Testing of emerging analgesic agents
  • Improving functional outcomes for patients with nerve pain

The research team of three investigators works to bring safer, more effective pain relief options to the community.

Nutritional and Metabolic Diseases

Studies address the growing burden of obesity, overweight, and type 2 diabetes by evaluating interventions that promote weight loss and better glycemic control.

  • Weight‑loss therapies for obesity and overweight
  • Combination treatments targeting diabetes and weight
  • Strategies to improve metabolic health
  • Long‑term management of chronic metabolic conditions

This research supports patients in achieving healthier body weight and blood sugar levels, reflecting the clinic’s commitment to metabolic well‑being.

Metabolism

The centre investigates how altering metabolic pathways can protect kidney function and reduce disease progression in individuals with chronic conditions.

  • Reduction of albuminuria in chronic kidney disease
  • Modulation of metabolic biomarkers in diabetes
  • Evaluation of renal outcomes linked to metabolic therapy
  • Exploration of novel mechanisms affecting metabolism

By linking metabolic research with cardiovascular and renal health, the site aims to deliver comprehensive benefits to patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Piotra Niedurnego 50 D41-709 Ruda SlaskaPoland
Recruiting now
5 trials
Conditions studied
8

More sites in Ruda SlaskaPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

12 clinical trials

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Obesity+1

Recruiting

A study to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight and type 2 diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Study on Balcinrenone and Dapagliflozin for Adults with Chronic Kidney Disease and Albuminuria

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Embonate
  • Sponsor:Novo Nordisk A/S

Obesity+1

Not recruiting

Study on Maridebart Cafraglutide for Adults with Type 2 Diabetes and Obesity or Overweight

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Diabetic neuropathy

Not recruiting

Study of LY3556050 for Adults with Diabetic Peripheral Neuropathy Pain

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LY3556050
  • Sponsor:Eli Lilly & Co.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.